Commentary on “Evaluation of Possible Carcinogenic Risk to Humans Based on Liver Tumors in Rodent Assays:The Two-Year Bioassay Is No Longer Necessary”

Toxicologic Pathology

Volumn 38, Issue 3, 2010, Pages 502-505

  Long, Gerald G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARCINOGEN; CHEMICAL COMPOUND; LIRAGLUTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

BIOASSAY; CARCINOGENESIS; CARCINOGENICITY; COST; EPIGENETICS; GENOTOXICITY; HAZARD ASSESSMENT; HUMAN; LIVER TUMOR; NONHUMAN; NOTE; PRECANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RODENT; SENSITIVITY AND SPECIFICITY; TIME; TOXICITY TESTING;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; CARCINOGENS; DISEASE MODELS, ANIMAL; HUMANS; LIVER NEOPLASMS; RISK; RODENTIA;

RODENTIA;

EID: 77952518772     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309359795     Document Type: Note

References (22)

1. Allen D. G. Pearse G. Haseman J. K. Maronpot R. R. (2004). Prediction of rodent carcinogenesis: An evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol Pathol 32, 393–401.
2. de Souza C. J. Eckhardt M. Gagen K. Dong M. Chen W. Laurent D. Burkey B. F. (2001). Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50, 1863–71.
3. El Hage J. (2005). Toxicity profiles of peroxisome proliferator-activated receptor (PPAR) agonists and preclinical safety profile for muraglitazar. http://www.fda.gov/ohms/dockets/ac/05/slides/2005-4169S2_02_02-FDA-ElHage_files/frame.htm.
4. Food and Drug Administration. (2009). FDA briefing materials, liraglutide, April 2, 2009. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf. Accessed June 9, 2009.
5. Gibson J. P. Sells D. M. Cheng H. C. Yuh L. (1987). Induction of uterine leiomyomas in mice by medroxalol and prevention by propranolol. Toxicol Pathol 15, 468–73.
6. Gopinath C. Gibson W. A. (1987). Mesovarian leiomyomas in the rat. Environ Health Perspect 73, 107–13.
7. Grommes C. Landreth G. E. Heneka M. T. (2004). Antineoplastic effects of peroxisome proliferators-activated receptor gamma agonists. Lancet Oncol 5, 419–29.
8. Hardisty J. F. Elwell M. R. Ernst H. Greaves P. Kolenda-Roberts H. Malarkey D. E. Mann P. C. Tellier P. A. (2007). Histopathology of hemangiosarcomas in mice and liposarcomas/fiborsarcomas in rats associated with PPAR agonists. Toxicol Pathol 35, 928–41.
9. Hellmold H. Zhang H. Anderson U. Blomgren B. Holland T. Berg A.-L. Elebring M. Sjögren N. Bamberg K. Dahl B. Westerberg R. Dillner B. Tugwood J. Roberts R. Lundholm E. Camejo G. Skånberg I. Evans J. (2007). Tesaglitazar, a PPAR a/g agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol Sci 98, 63–74.
10. Herman J. R. Dethloff L. A. McGuire E. J. Parker R. F. Walsh K. M. Gough A. W. Masuda H. de la Iglesia F. A. (2002). Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol Sci 68, 226–36.
11. Holsapple M. P. Pitot H. C. Cohen S. M. Boobis A. R. Klaunig J. E. Pastoor T. Dellarco V. L. Dragan Y. P. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 89, 51–56.
12. Jack D. Poynter D. Spurling N. W. (1983). Beta-adrenoceptor stimulants and mesovarian leiomyomas in the rat. Toxicology 27, 315–20.
13. Krewski D. Andersen M. E. Mantus E. Zeise L. (2009). Toxicity testing in the 21st century: Implications for human health risk assessment. Risk Anal 29, 474–79.
14. Long G. G. Reynolds V. L. Dochterman L. W. Ryan T. E. (2009). Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a γ-dominant PPAR α/γ agonist. Toxicol Pathol 37, 741–53.
15. Na H. Surh Y. (2003). Peroxisome proliferator-activated receptor γ (Pparγ) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 66, 1381–91.
16. National Research Council. (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. National Academy Press, Washington, DC.
17. Nordisk Novo. (2009). Liraglutide (injection) for the treatment of patients with type 2 diabetes, NDA 22-341, briefing document: Endocrine and Metabolic Drug Advisory Committee, April 2, 2009. http://www.fda.gov//Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM148659.pdf. Accessed June 9, 2009.
18. Panigrahy D. Shen L. Q. Kieran M. W. Kaipainen A. (2003). Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 12, 1925–37.
19. Peraza M. A. Burdick A. D. Martin H. E. Gonzalez F. J. Peters J. M. (2006). The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci 90, 269–95.
20. Randerath K. Moorthy B. Mabon N. Sriram P. (1994). Tamoxifen: Evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15, 2087–94.
21. Tannehill-Gregg S. H. Sanderson T. P. Minnema D. Voelker R. Ulland B. Cohen S. M. Arnold L. L. Schilling B. E. Waites C. R. Dominick M. A. (2007). Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar. Toxicol Sci 98, 258–70.
22. Tryndyak V. P. Muskhelishvili L. Kovalchuk O. Rodrigues-Juarex R. Montgomery B. Churchwell M. I. Ross S. A. Beland F. A. Pogribny I. P. (2006). Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: Implications for tamoxifen-induced hapatocarcinogenesis. Carcinogenesis 27, 1713–20.